Post a Free Blog

Submit A Press Release

Friday, March 29, 2024
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
-- Advertisement --spot_img
HomeBusinessBIOL Earnings. Should You Buy?

BIOL Earnings. Should You Buy?

Credit Twitter

 

 

BIOLASE, Inc.  (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the fourth quarter and full year ended December 31, 2020.

BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

2020 Fourth Quarter Operating Highlights and Recent Developments:

  • Total revenue was $8.5 million, representing sequential quarterly growth of 31%.
  • U.S. revenue exceeded the prior-year fourth quarter, despite COVID-19 headwinds.
  • 78% of sales came from new users, continuing a positive trend.
  • 40% of sales came from dental specialists, a significant increase compared to recent prior periods.
  • Several Dental Services Organizations (“DSOs”) purchased  BIOLASE  products in the fourth quarter, including Heartland Dental, Dental Care Alliance, Aspen Dental and Virginia Family Dentistry.
  • BIOLASE  significantly bolstered its balance sheet during the COVID-19 pandemic as cash and cash equivalents totaled $17.9 million on December 31, 2020.
  • The Company completed a $14.4 million bought deal in February 2021 increasing its current cash and cash equivalents to approximately $40.0 million as of February 28, 2021, including the proceeds from the exercise of warrants sold in the Company’s July 2020 rights offering.

“Our strong fourth quarter revenue performance is our second consecutive quarter of significant sequential growth and was driven by sales to new customers, dental specialists and DSOs in the U.S.,” commented John Beaver, President and Chief Executive Officer. “Dental specialists, such as endodontist and periodontists, comprised 40% of our U.S. laser sales in the fourth quarter, reflecting our ongoing efforts to educate and train these dental specialists on the benefits of our lasers to drive increased adoption. Our industry-leading dental lasers provide a new, improved and better standard of care for dental procedures while ensuring a safer environment for dental practitioners and patients by reducing aerosolization to mitigate the spread of infectious pathogens, such as COVID-19. We are experiencing high demand from dental specialists for our advanced dental lasers because these products provide the opportunity they seek for safer, more advanced alternatives to grow their practices.

“We have continued to make adjustments to our go-to-market approach during the pandemic, and the momentum we are seeing in the current 2021 first quarter gives us greater confidence that we are nearing a resumption of the growth we were generating prior to COVID-19. Specifically, despite the ongoing impact of the pandemic, we expect to report total revenue growth of approximately 65% for the current first quarter compared to the same quarter a year ago.”

2020 Fourth Quarter Financial Results

Net revenue for the fourth quarter of 2020 was $8.5 million, an increase of 31% sequentially from third quarter revenue of $6.5 million. Compared to the year-ago fourth quarter, which was the last full quarter prior to the impact of the COVID-19 pandemic, revenue decreased 17% from $10.2 million. U.S. laser revenue was $3.8 million for the fourth quarter of 2020, up 15% when compared to U.S. laser revenue of $3.3 million for the fourth quarter of 2019. U.S. consumables and other revenue for the fourth quarter of 2020, which consists of revenue from consumable products such as disposable tips, decreased 10% compared to the fourth quarter of 2019. Outside the U.S., laser revenue declined 52% to $1.7 million for the fourth quarter of 2020 compared to $3.5 million for the fourth quarter of 2019, and consumables and other revenue decreased 13% year over year as recovery from the pandemic has come slower internationally.

Gross margin for the fourth quarter of 2020 was 19%, compared to 43% for the fourth quarter of 2019. The lower gross margin reflects the impact of a decline in revenues relative to our fixed costs and a $1.0 million expense for inventory obsolescence. These impacts were partially offset by higher average U.S. selling prices of our lasers. Total operating expenses were $7.1 million for the fourth quarter of 2020 compared to $7.5 million for the fourth quarter of 2019, a decrease of approximately 5%. Operating loss for the fourth quarter of 2020, was $5.5 million, compared to an operating loss of $3.0 million in the fourth quarter of 2019. Net loss for the fourth quarter of 2020 was $6.1 million, or $0.07 per share, compared to a net loss of $3.6 million, or $0.13 per share, for the fourth quarter of 2019.

Full Year 2020 Financial Results

Net revenue for the year ended December 31, 2020 was $22.8 million, a decrease of 40% compared to net revenue of $37.8 million for the year ended December 31, 2019. U.S. laser revenue was $8.3 million for the year ended December 31, 2020, a decrease of 25% compared to U.S. laser revenue of $11.1 million for the year ended December 31, 2019. U.S. consumables and other revenue for the year ended December 31, 2020, which consists of revenue from consumable products such as disposable tips, decreased 29% year over year. International laser revenue decreased to $4.0 million for the year ended December 31, 2020 compared to $11.7 million for the year ended December 31, 2019.

Gross margin for the year ended December 31, 2020 was 27% compared to 38% for the year ended December 31, 2019. Total operating expenses were $24.7 million for the year ended December 31, 2020 compared to $29.9 million for the year ended December 31, 2019, a decrease of $5.2 million, or 17%, year over year. Operating loss for the year ended December 31, 2020 was $18.5 million, compared to an operating loss of $15.6 million for the year ended December 31, 2019, an increase of $2.9 million year over year. Net loss for the year ended December 31, 2020 was $16.8 million, or $0.28 per share, compared to a net loss of $17.9 million, or $0.77 per share, for the year ended December 31, 2019.

Adjusted EBITDA — Use of Non-GAAP Measures

The Reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company’s non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company’s Adjusted EBITDA and Adjusted EBITDA per share.

Adjusted EBITDA loss for the fourth quarter of 2020 was $4.5 million, or $0.05 per share, compared with Adjusted EBITDA loss of $1.7 million, or $0.05 per share, for the fourth quarter of 2019.

Adjusted EBITDA for the year ended December 31, 2020 was a loss of $13.4 million, or $0.22 per share, compared with an Adjusted EBITDA loss of $10.3 million, or $0.45 per share, for the year ended December 31, 2019.

2021 First Quarter Revenue Guidance

For the first quarter ending March 31, 2021, the Company expects total revenue of $7.5 million to $8.0 million, which would represent growth between 60% and 70% year over year.

Conference Call Information

BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the fourth quarter and full year ended December 31, 2020, and to answer questions. For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 800-353-6461. For international participants outside the U.S./Canada, the dial-in number is 334-323-0501. For all callers, refer to the Conference ID 7623727. To access the live webcast, visit the Investor Relations section of the  BIOLASE  website at  www.biolase.com  and see “Investor Events”.

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the  BIOLASE  website.

About  BIOLASE

BIOLASE  is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications.  BIOLASE  has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

Subscribe to get Latest News Updates

Latest News Articles

You may like more
more

Semtech Shares Jump 3 percent Following Q4 Results

Semtech (NASDAQ:SMTC) experienced a more than 3% increase in...

Target Stock Added to Fresh Money List at Deutsche Bank

Deutsche Bank analysts placed Target (NYSE:TGT) on the Fresh...

AMC Shares Plunge 14 percent on a New Equity Distribution Deal

AMC Entertainment Holdings (NYSE:AMC) saw its shares drop over...

Palantir Technologies Stock Drops 6 percent on Monness, Crespi, Hardt Downgrade

Palantir Technologies (NYSE:PLTR) stock plunged more than 6% on...